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In the management of Acute Heart Failure (AHF) patients, current guidelines suggest making prompt clinical 
assessments that include patient’s congestion and perfusion status evaluation, in order to start appropriate 
treatments. Unfortunately, so far, an accurate evaluation of the hemodynamic and fluid status of AHF patients is 
only possible using invasive methods; consequently, there is an unmet need for noninvasive technologies to easily 
detect different phenotypes of AHF subjects based on different cardiac hemodynamic profiles. Technological 
advances such as Biva, Nexfin, or NICas could allow for routine non-invasive continuous monitoring of Cardiac 
Hemodynamic and Fluid content in Acute Heart Failure patients. These non-invasive measurements may provide 
important information for improving diagnosis, developing individualized therapeutic management plans/dispo-
sition decisions, and predicting short term mortality
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 Acute heart failure (AHF) is defined as rapid, new-onset, or 
worsening presentation of the symptoms and signs of heart failure (HF) 
resulting from any structural or functional impairment of the left 
ventricle.1 It is a growing epidemic, with an estimated 670,000 new 
cases/year in the USA, and more than 15 million patients in Europe and 
represents also the leading cause of acute hospitalizations. Moreover, 
patients hospitalized with AHF suffer high rates of post-discharge 
re-hospitalizations (20–30%) and mortality (10–20%) within 3–6 
months. Ultimately, AHF has a negative impact on both patient 
outcomes and health care systems costs.1
 In AHF, systemic congestion is both a cause and result of 
worsening cardiovascular function Being the total body fluid overload 
the consequence of the activation of the neurohormonal system that 
then causes fluid redistribution and accumulation, increases systemic 
resistance, and reduces capacitance in large veins.  Ultimately, these 
pathophysiological changes lead to clinical decompensation and are 
associated with elevations of b-type natriuretic peptides (NP’s).2
 Total body fluid overload is not only a benchmark for AHF 
diagnosis, but also for its prognosis.3
 Different non-invasive methods for assessing clinical conges-
tion are available (e.g., accurate physical examination, chest X-ray, 
thorax and inferior vena cava index, and chest ultrasound evaluation,
however, they suffer from low sensitivity, insufficient specificity, and 
poor interrater reliability.  Although chest ultrasound seems to be 
accurate in detecting lung congestion, it is very difficult to accurately 
assess total body water content and organ perfusion and it currently is 
estimated predominately on the basis of blood pressure.4
 Current guidelines support treatments based on physician 
clinical assessments that include the immediate accurate evaluation of 
a patient’s congestion and perfusion status, being this assessment 
necessary to start appropriately tailored treatments, mainly with diuret-
ic and vasodilator drugs.1,5
 Literature has shown that the prediction of the underlying 
hemodynamic profiles by cardiologists, intensivists, and emergency 
physicians using clinical evaluation alone is neither accurate nor 
reliable.6-8 As consequence, while profiling of AHF patients based on 
clinical assessment of central congestion and peripheral perfusion 
(warm/dry, warm/wet [most patients], cold/dry or cold/wet) is 
proposed for rapid ED therapeutic decision making, there is only fair to 
poor interrater agreement for related categorical assignments.9
Bioimpedance Vector Analysis
 All biological structures have a specific resistance, defined as 
the strength of opposition by tissue to the electric current flow. 
Bioimpedance vector analysis (BIVA) uses 4 electrodes to noninvasively 
measure impedance using a 300 μA, 50 kHz current, the results of
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Figure 1. BIVA Measurement and Result15
Figure 2. Additive Value of BIVA compared to other methods15
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which correlate to body volume and composition.  Bioelectrical imped-
ance (Z) consists of two components, resistance (Rz) and reactance 
(Xc).) The mathematical solution to providing clinical data requires 
that the human body is approximated as the sum of five interconnected 
cylinders that act as conductors in parallel. While Rz is inversely related 
with the amount of total body water, Xc is considered proportional to 
body mass.10,11
 To obtain BIVA measurement, two electrodes, 5 cm apart, 
are placed on the wrist and ipsilateral ankle in the supine subject. To 
prevent inaccurate results, the patient must avoid extremity contact 
with the trunk and with the stretcher. (Figure 1)
 
 As fluids are good conductors, the length of the Z vector 
(representing the body’s impedance), is inversely related to fluid 
volume. Several studies have agreed on the delineation of the 75% 
tolerance ellipse as the boundary of normal tissue hydration.12 
Consequently, vectors outside the upper pole of the 75% ellipse 
indicate dehydration, whereas vectors outside the lower pole of 75% 
confidence ellipse represent overhydration (Figure. 2), and shorter the 
vector, more severe is the condition of fluid overload.
 In AHF patients, BIVA results are strongly related to b-type 
natriuretic peptide (BNP) values, New York Heart Association (NYHA) 
functional classes, and CVP. More importantly, it allows physicians to 
detect fluid overload even before the appearance of peripheral edema, 
thus potentially allowing treatment before the development of severe 
symptoms.13
 Results from our group confirmed the additive diagnostic 
value of BIVA in easily and quickly detecting AHF.14 As summarized in 
figure 3, patients’ vectors were grouped as 95% confidence interval (CI) 
ellipses of point vectors (Figure 3). While the white ellipses of the 
no-AHF cohort demonstrated normal hydration status (inside the 50% 
ellipse) in both sexes, for congestive patients (grey ellipses) the 95% CI 
ellipse was displaced along the major axis, and between 75 and 95% 
ellipses both for females and males, indicating body fluid congestion 
(Figure 3). At ED admission, versus the no-AHF cohort, the mean 
hydration index (HI) was higher in the AHF group (81.2 ± 6.7% vs. 
72.9 ± 3.6%, <0.001), while mean Xc/H and Rz/H values were signifi-
cantly lower in congestive patients (p <0.001). 
 It has been demonstrated that combining BIVA plus BNP may 
2
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in cardiac and intensive critical unit settings and also to evaluate AHF 
patients.19
 The invasive Swan-Ganz pulmonary artery catheterization 
(PAC) thermodilution technique is considered the gold standard, 
despite controversies.   For the past three decades, the measurement of 
hemodynamic profiles of patients has been limited to the critical care 
units because the measurement methods used were invasive in nature 
and/or complex to apply and time-consuming (pulmonary artery 
catheter).20  Thus acutely ill or injured patients in the ED may have 
suboptimal physician clinical hemodynamic assessments made and 
with an unknown effect on patient outcomes in a variety of disease 
states.  Consequently, a critical need exists for a non-invasive, inexpen-
sive, reliable, and practical technique for measuring hemodynamic 
parameters in AHF patients.21
 
 A regional bioimpedance cardiography device (NiCaS, NI 
Medical, Israel) has been validated in the cardiac care setting.22,23   It 
has been shown to have better accuracy and precision compared with 
thoracic bioimpedance and modified-Fick techniques. This may 
represent a breakthrough technology capable of measuring hemody-
namic parameters including cardiac output, cardiac power, total 
peripheral resistance, and total body water based on regional 
bioimpedance.
 NiCaS transmits an imperceptible electrical signal through 
the blood in the arterial system through two sensors arranged in a 
wrist-to-ankle configuration (figure 4).  With each heartbeat, the 
volume of blood in the arterial system changes and results in a change 
in the body electrical resistance. Because the volume of moving fluid is 
associated with resistance changes, NiCaS can calculate cardiac output 
by integrating the area under the time-resistance curve multiplied by 
the heart rate well. From these parameters, other hemodynamic and 
respiratory outputs can be calculated.  NiCaS measurements are non-in-





 A novel monitoring device (Nexfin; BMEYE, Edwards 
Lifesciences, Irvine, California) to noninvasively and continuously 
measure beat-to-beat hemodynamic measurements in ED adult patients 
with clinically suspected AHF has been recently available.24-26  Cardiac 
output and other hemodynamic variables are determined from a 
reconstructed brachial artery waveform using the Nexfin COTrel pulse 
contour method [and systemic vascular resistance (SVR) is calculated. 
These are displayed beat-to-beat, time-averaged, trended, and indexed 
by height and weight. The Nexfin device has been shown to have 
acceptable measurements [limits of agreement of up to ±30%] for 
cardiac output when compared to invasive pulmonary artery catheter 
measurements (figure 7)
 
 The Premium Registry using Nexfin in ED AHF subjects 
showed that AHF patients with similar clinical parameters available in
 It has been demonstrated that combining BIVA plus BNP may 
improve the management of AHF patients in ED, compared to BNP 
alone. When considered separately, BNP is internationally recognized 
to be associate with increased left ventricle pressure and volume 
overload, while the HI, obtained using BIVA, is proportional to total 
body fluid congestion.15 As BNP and BIVA data provide information on 
different aspects of cardiovascular function, their combined measure-
ment may lead to earlier and more accurate AHF diagnosis. This may be 
especially relevant when the BNP result is in the “gray zone”, between 
100 and 400 pg/mL, where it has lower diagnostic accuracy.16
 Other environments have recommended the adoption of 
BIVA. Patients with HF complicated by renal dysfunction termed 
“cardiorenal syndrome” represent a management challenge for whom 
the evaluation of total body fluid is fundamental.17,18 
 The prognostic value of BIVA in patients with AHF  was also 
confirmed in a shorter follow-up period (30 days) and with a hydration 
assessment obtained at the moment of a patient’s arrival at ED.  An HI 
value greater than 74.3% was associated with worse 30-day 
outcomes.16
Whole Body (Regional) Impedance Cardiography (NICaS).
 Millions of acutely ill patients are evaluated in theEmergency 
Department (ED) by clinicians who utilize vital signs and clinical 
evaluation to estimate underlying hemodynamic profiles. Based on 
these evaluations, a diagnostic and therapeutic plan is formulated for 
each patient.5,8  However, blood flow (cardiac index) is not reliably 
inferred from vital signs.  
 Hemodynamic parameters, such as stroke volume (SV) and 
cardiac output (CO), are an essential component of fluid management
short-term mortality.
Take Home Messages 
 
 
Figure 3. BIVA Result Interpretation
Figure 4. NICaS Component
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the ED have different underlying hemodynamic profiles.9 These may be 
clustered into three separate phenotypes. Importantly, ED phenotype 
clusters could not be reliably recognized through the use of current 
clinical ED assessments and laboratory testing. Although the Premium 
observational registry was not powered for outcomes there were 
trendsto more and relatively high rates of in-hospital (10%) and 30 
days (20%) deaths in cluster 3 vs. other groups. This may be explained 
as a result of diuretic therapy in patients with low cardiac output in the 
face of markedly increased systemic vascular resistance. 
 In this attempt, The Nexfin device has been shown to have 
acceptable measurements [limits of agreement of up to ±30%] for
cardiac output when compared to invasive pulmonary artery catheter 
measurements. Unfortunately, in patients with very low cardiac output 
(e.g., shock) finger perfusion may be too low to properly detect the 
device signal and thus in this situation, it may not be considered as an 
ideal monitor. Conversely, NIcas technology has been shown to be a 
very good tool in monitoring therapeutic efficacy.  Ultimately, NIcas 
could provide a very good estimation of total body fluid content and 
could be considered the more appropriate tool for non-invasively 
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Figure 5. Whole Body (Regional) Impedance Cardiography
Figure 6. NICaS Parameters
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Figure 7. NEXFIN System
 In AHF patients a delay in ED treatment has been associated 
with an increase in acute mortality and hospital length of stay.  Conse-
quently, fast and accurate evaluation of organ perfusion and total body 
congestion, consistent with the current ESC guidelines, are needed to 
start a tailored treatment using diuretic, vasodilators, or inotropic 
drugs. Clinical evaluation for the presence of peripheral edema, jugular 
vein distention, hepato-jugular reflux), lung rales, or the S3, are of 
great utility for therapeutical decision making.8 
 One of the most common diagnostic tools for detecting 
clinical congestion is the chest X-ray, which is commonly recommended 
and routinely performed. Nevertheless, in 86,376 patients from the 
ADHF Registry (ADHERE), the frequency of patient admission with 
negative chest radiography exceeded that of patients with positive 
chest radiography such that it is not possible to exclude the presence of 
congestion with a normal Chest Xray.31 In an expert consensus 
document of the Group of the Acute Cardiovascular Care Association 
and the Committee of Acute Heart Failure from the Heart Failure 
Association of the European Society of Cardiology, the role of Echocar-
diography and lung ultrasonography for the proper assessment of 
congestion and cardiac hemodynamics has been clearly demonstrated.4  
However, issues on total body fluid content, cardiac output, and total 
peripheral resistance evaluations are still unsolved.  Ultrasound
technology has confirmed that, on the basis of vector length by BIVA 
measurement, it is possible to distinguish between dyspneic patients 
with and without AHF.  
 
 Natriuretic peptides (NPs) are widely used and recommend-
ed in AHF.1 Their diagnostic role is a function of the relationship with 
intravascular pressure and volume overload, where they are used as a 
surrogate for cardiac hemodynamics of fluid overload. 
 One promising strategy is the combination of BIVA and BNP. 
This is because BIVA provides a more accurate estimation of peripheral 
congestion than BNP, while BNP provides superior prognostic charac-
teristics. Therefore, BIVA in combination with BNP may be a fundamen-
tal tool, in consideration with the physical examination, in order to 




 In summary, technological advances such as Biva, Nexfin, or 
NICas could allow for routine non-invasive continuous monitoring of 
Cardiac Hemodynamic and Fluid content in Acute Heart Failure 
patients. These initial non-invasive measurements may provide
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important information for improving diagnosis, developing individual-
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An integrated approach to assess congestion by means of Biomark-
ers plus simple, non-invasive, highly reproducible methods (Natri-
uretic Peptides,  +BIVA, Echocardiogram, LUS, and IVC US) would 
be more  useful;
Invasive hemodynamic monitoring (Swan Ganz) is still considered 
of utility, but should not be used as a routine procedure (high cost, 
invasive).
Compared to currently used tools, New Biomarkers of Congestion 
such as Bio Adrenomedullin32 together with Non- invasive cardiac 
hemodynamic and total fluid status monitoring by NICaS could 
provide Better Diagnostic and prognostic value (in-hospital mortali-
ty and readmission) also allowing monitoring of decongestion 
efficacy and organ perfusion of used treatment.  
Further clinical studies are needed to confirm the real utility of all 
the actual used devices of non-invasive cardiac hemodynamics 
measurements in AHF patients in a wider numeric sample and 
multicentric study and to determine how to best use them.
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